Well Referenced

Tag: real-world data

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients

This observational study assessed the cost-effectiveness of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Among 118 patients (mean age 63.8, 55.1% male), those receiving Viscum album plus chemotherapy had a longer adjusted mean overall survival (19.1 months) compared

Read More »
June 26, 2025 No Comments

Safety of Combined Targeted and Helixor®Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study

This observational study examined the safety of combining Helixor® Viscum album L. (a mistletoe extract) with targeted therapy in breast and gynecological cancer patients. The study included 242 patients, with 160 receiving only targeted therapy and 82 receiving a combination of targeted therapy and Helixor® Viscum album L. therapy. Results

Read More »
June 26, 2025 No Comments